(Reuters) – Drugmakers AstraZeneca Plc and Merck & Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer.
The recommendation from the EMA’s Committee for Medicinal Products for Human Use was based on positive results from a late-stage trial, where Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Vinay Dwivedi)
